photoaging facial rejuvenation
Conditions
Interventions
A 20 mL of blood were drawn from volunteer via Cephalic or Basilic veins using a 2 mL ACD-A (Acid citrate dextrose solution A) filled syringe. The mixture of blood and ACD-A was transferred to PRP Tu
0.5-1 mL for cheek area, 0.25-0.5 mL for periorbital area and 0.25-0.5 mL for nasolabial area.
,A 20 mL of blood were drawn from volunteer via Cephalic or Basilic veins using a 2 mL ACD-A (Acid citrat
0.5-1 mL for cheek area, 0.25-0.5 mL for periorbital area and 0.25-0.5 mL for nasolabial area.
Experimental Device,Active Comparator Device
Photobiomodulated PRP with 467 nm light,PRP
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Male or female, aged 30 to 60 years. 2. Willing to participate voluntarily in the study. 3. Thai of Asian descent with Fitzpatrick Skin Type III to V. 4. Assessed by a board-certified dermatologic surgeon to have moderate or higher degrees of photoaging, according to the Glogau classification of photoaging
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding women, as determined by menstrual history and method of contraception. 2. Participants with a history of hematologic disorders, coagulation abnormalities, anemia, liver disease, cancer, or autoimmune diseases. 3.Participants who smoke or have a history of heavy alcohol consumption. 4. Participants with dermatitis, wounds, or skin infections on the face. 5. Participants with a history of allergy to local anesthetics. 6.Participants with a history of hormone use or contraceptive use (injection or oral forms), or regular use of NSAIDs. 7. Participants who are taking medications affecting blood coagulation, such as aspirin or anticoagulants. 8.Participants who have taken anti-inflammatory or antiplatelet medications within 72 hours prior to treatment. 9. Participants with a history of facial lifting procedures, including energy-based devices or thread lifting, within 6 months prior to study participation. 10. Participants with a history of dermal filler injections on the face within 6 months prior to study participation. 11. Participants with a history of platelet-rich plasma (PRP) injections on the face within 6 months prior to study participation. 12. Participants with a history of botulinum toxin injections on the face within 6 months prior to study participation. 13. Participants with a history of collagen-stimulating laser treatments on the face within 6 months prior to study participation. 14. Participants with a history of hypertrophic scars. 15. Participants who have used sex hormone therapies (topical, oral, injectable, or implant forms) within 6 months prior to study participation. 16. Participants diagnosed with a psychiatric disorder by a psychiatrist. 17. Participants who do not consent to photography for treatment evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fine lines Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1-, 3- and 6-month after complete treatment Antera 3D,Wrinkles Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1-, 3- and 6-month after complete treatment Antera3D,Folds Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1-, 3- and 6-month after complete treatment Antera3D,Texture (Roughnes) Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1-, 3- and 6-month after complete treatment Antera3D,Cutometry Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1-, 3- and 6-month after complete treatment Cutometer,Blinded evaluator assessment 1 month after 1st treatment, 1 month after 2nd treatment, 1-, 3- and 6-month after complete treatment Quartile scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient improvement scale 1 month after 1st treatment, 1 month after 2nd treatment, 1-, 3- and 6-month after complete treatment Quartile scale,Skin hydration Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1-, 3- and 6-month after complete treatment Corneometer,Individual typology angle (ITA) Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1-, 3- and 6-month after complete treatment Colorimeter,Sebum level Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1-, 3- and 6-month after complete treatment Sebumeter,Safety Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1-, 3- and 6-month after complete treatment Adverse events | — |
Countries
Thailand
Contacts
Public ContactRungsima Wanitphakdeedecha
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Outcome results
None listed